Verve Hits The Clinic With Gene-Edited Cholesterol-Lowering Drug

 
• By Alaric DeArment
  
Verve announced the dosing of the first patient in the trial of its Phase Ib study of VERVE-101 in HeFH • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies